What is IHC, and why is it important?

IHC is a method that employs antibodies to identify particular proteins in tissue samples. It's a vital tool in medical research and clinical diagnostics because it allows scientists and doctors to see where proteins are located within cells and tissues. This information is vital for understanding how diseases develop, diagnosing conditions like cancer, and developing new treatments.

Why is it challenging to develop antibodies specifically for IHC?

Developing antibodies for IHC is more complex than for other techniques due to several factors. Tissue processing can alter the shape of proteins, making it difficult for antibodies to recognize them. IHC also requires antibodies to be highly specific to avoid binding to other proteins in the tissue, which would lead to inaccurate results. Additionally, the antibodies need to penetrate the tissue effectively and remain stable throughout the IHC process.

How does your company ensure the specificity of the IHC antibodies you produce?

We employ several strategies to ensure high specificity. We start with careful antigen design and preparation. Then, we use stringent screening processes, including IHC-specific assays, to select antibodies that bind only to the target protein in tissue sections. We also perform extensive validation testing, including comparing staining in positive and negative control tissues, to confirm specificity.

What types of antigens can be used to generate IHC-positive antibodies?

We can use a variety of antigens, depending on the specific project requirements. Common antigen types include recombinant proteins, synthetic peptides, and even denatured antigens, such as fixed tissue samples. The choice of antigen is crucial and is tailored to elicit the most effective antibody response for IHC applications. We consider factors such as protein structure and potential modifications during tissue processing.

What is IHC-positive hybridoma screening?

IHC-positive hybridoma screening is a specialized screening process we use to identify hybridoma clones that produce antibodies that work well in IHC. Unlike general antibody screening, this method directly tests the antibodies' performance on tissue sections. We also use tissue microarrays for hybridoma screening. This ensures that we select only antibodies that can effectively bind to the target protein in its native tissue context.

What kind of tissue samples are suitable for testing the antibodies?

We can work with a wide range of tissue samples, including formalin-fixed, frozen tissue, and paraffin-embedded (FFPE) tissue sections. The specific type of tissue sample used for testing will depend on the client's research or diagnostic needs. We also optimize our protocols to ensure that the antibodies perform well with the client's specific tissue types.

IF Positive Antibody Discovery Service

Overview Service Published Data Features FAQ

Creative Biolabs offers IF-positive antibody discovery service for generating high-quality, application-specific antibodies crucial for immunofluorescence (IF) assays. Leveraging advanced hybridoma technology and a dedicated team, we deliver tailored solutions. We empower researchers with reliable tools, accelerating their discoveries and advancing scientific understanding.

Overview of IF and IF Antibodies

The IF represents a vital technique in biological research and diagnostics, enabling the visualization and localization of specific proteins and antigens within cells and tissues. This technique relies on the use of antibodies conjugated to fluorescent dyes, which bind to target molecules, allowing for their detection under a fluorescence microscope. The specificity of the antibody-antigen interaction is paramount in IF, as it directly impacts the accuracy and reliability of the results.

Fig.1 IF and H&E. (Lin, et al., 2023) Fig.1 Same-section IF and H&E staining.¹

IF antibodies are specialized reagents designed to meet the stringent requirements of immunofluorescence assays. These antibodies must exhibit high specificity to minimize background staining and cross-reactivity, ensuring precise target identification. Furthermore, they need to be compatible with various fixation and permeabilization methods used in IF sample preparation. The quality of IF antibodies significantly influences the resolution and sensitivity of the assay, making their selection a critical factor in experimental design. Researchers depend on high-quality IF antibodies to accurately interpret cellular processes, diagnose diseases, and advance understanding of biological systems.

Features of our IF-Positive Antibodies

High specificity, ensuring minimal background staining.
Optimized for various fixation and permeabilization protocols.
Consistent and reliable performance in IF assays.
Enhanced signal-to-noise ratio for clear visualization.
Rigorous quality control and validation.

IF-Positive Hybridoma Based Antibody Discovery Service

We provide customized services to meet your specific project requirements. Our scientists collaborate closely with you to understand your target antigen, experimental design, and desired antibody characteristics. We understand the critical role of antibody specificity and performance in IF, and our service is designed to deliver antibodies that meet the highest standards.

Antigen Preparation

The process begins with meticulous antigen preparation. Recognizing that antigen conformation can significantly affect antibody binding, especially in IF where proteins are often fixed, we employ strategies to optimize antigen presentation. We consider the impact of fixation and embedding on antigen structure and, if necessary, utilize fixative-treated immunogens.

Animal Immunization

Following antigen preparation, we proceed with animal immunization. Our immunization protocols are designed to elicit a robust and specific immune response against the target antigen. We carefully select adjuvants and optimize immunization schedules to maximize the production of high-affinity antibody-producing B cells.

Hybridoma Generation

Splenocytes from immunized animals are then fused with myeloma cells to generate hybridomas. This fusion process creates immortalized cell lines that produce monoclonal antibodies. Our optimized fusion protocols ensure a high fusion efficiency, leading to a diverse pool of hybridoma clones.

Hybridoma Screening

A critical step in our service is the rigorous screening of hybridoma clones. We employ a multi-tiered screening approach to identify clones that produce antibodies with the desired specificity and affinity for IF applications. Initially, we utilize assays such as ELISA, Western blotting, and immunoprecipitation to select clones with favorable binding properties.

IF Assay Validation

Importantly, we go beyond traditional screening methods. The selected antibodies undergo direct scrutiny in IF assays using relevant cell and tissue samples. This step ensures that the antibodies exhibit the required staining patterns, high signal-to-noise ratios, and minimal background. We compare staining intensity against isotype-matched negative controls to confirm specificity.

Clone Expansion and Antibody Production

Hybridoma clones that demonstrate excellent performance in IF assays are then expanded to generate sufficient quantities of antibodies. We utilize optimized cell culture methods to maximize antibody yield while maintaining antibody quality.

Antibody Purification and Delivery

Finally, the antibodies are purified to the highest standards, using techniques such as affinity chromatography. We provide purified antibodies along with comprehensive data, including antibody titer, specificity, and IF validation results.

Published Data

Images of IHC and uniplex IF. Fig.2 Microphotographs of representative examples of validation from uniplex IHC and uniplex IF.²

After conducting chromogenic IHC and uniplex IF staining to examine all the markers, Parra, Edwin R., et al. further validated these markers through multiplex IF staining in two distinct panels². To substantiate their findings, they presented microphotographs showcasing representative instances of validation derived from uniplex IHC, uniplex IF staining that highlighted tumor-associated immune cell expression, and intricate details of uniplex IF staining in tonsil tissue.

Features of our Service

Application-Specific Development: We provide tailored antibody development, optimized specifically for immunofluorescence applications, ensuring superior performance in your IF assays.
Comprehensive Workflow: Our service covers every stage of the process, from meticulous antigen preparation to the final delivery of purified, characterized antibodies, providing a seamless experience.
Rigorous Validation: We employ a rigorous multi-step screening process, with a key focus on direct IF assay validation, to guarantee the specificity and reliability of the antibodies we deliver.
Expert Consultation: Our team offers expert consultation and close collaboration throughout the project, customizing our services to meet your unique research needs and experimental design.
High-Quality Deliverables: You can expect the delivery of high-quality, well-characterized antibodies, accompanied by comprehensive data, ensuring confidence in your results.

FAQ

Q: What types of antigens can you use for IF antibody development?
We have extensive experience in working with a wide range of antigens, including recombinant proteins, peptides, and even complex antigens such as cell lysates and tissue sections. Our scientists can also assist with antigen preparation, including fixation and other treatments necessary for optimal performance in IF assays. We adapt our protocols to the specific characteristics of your antigen.
Q: How do you ensure the specificity of the antibodies for IF?
Ensuring specificity is paramount for IF applications. We employ a multi-faceted approach. Initially, we use techniques like ELISA, Western blotting, and immunoprecipitation to select clones with high affinity to the target. Crucially, we validate the antibodies directly in IF assays using appropriate control tissues and cells. This validation step confirms that the antibodies exhibit the correct staining pattern and minimal background staining.
Q: Can you provide antibodies for multiplex IF assays?
Yes, we can develop antibodies suitable for multiplex IF assays. Our screening and validation processes can be adapted to identify antibodies with distinct specificities and minimal cross-reactivity, which is essential for successful multiplexing. We work closely with you to ensure that the antibodies meet the specific requirements of your multiplexing experiments.
Q: How do you handle challenging antigens, such as membrane proteins?
We have specialized protocols for handling challenging antigens, including membrane proteins. These protocols may involve using specific detergents, liposomes, or cell-based immunization strategies to ensure proper antigen presentation and elicit a robust immune response. We also employ screening methods that are suitable for detecting antibodies against these difficult targets.
Q: What quality control methods have you put in place?
We maintain strong quality control methods throughout the antibody development process. These measures include rigorous testing of reagents, validation of assay performance, and thorough documentation of all procedures. We also perform multiple rounds of antibody characterization to ensure the quality and reproducibility of the final product.
Q: What kind of post-service support do you offer?
We are committed to providing ongoing support to our clients. Our team of experts is available to answer any questions you may have and provide technical assistance with your IF experiments. We also offer additional services, such as antibody conjugation and further characterization, to support your research needs.

Our extensive experience in antibody development and optimized antibody functional verification strategies allow us to provide you with high-quality IF antibody products. Our functional validation ensures the specificity and affinity of the desired antibody. If you are in urgent need of cost-effective IF antibody development services, please feel free to contact us.

References

Lin, Jia-Ren, et al. "High-plex immunofluorescence imaging and traditional histology of the same tissue section for discovering image-based biomarkers." Nature Cancer 4.7 (2023): 1036-1052. Distributed under Open Access license CC BY 4.0. The image was modified by extracting and using only a and b sections of the original image.
Parra, Edwin R., et al. "Validation of multiplex immunofluorescence panels using multispectral microscopy for immune-profiling of formalin-fixed and paraffin-embedded human tumor tissues." Scientific reports 7.1 (2017): 13380. Distributed under Open Access license CC BY 4.0, without modification.

All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.

	USA: Europe: Germany:
	Call us at: USA: UK: Germany:
	Fax:
	Email: